SCHEMBL24257592

SCHEMBL24257592

Cc1c(-c2cnn(C(C)C)c2)cnc(C#N)c1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.37
PDK2 Q15119 1/20 0.36
SCN9A Q15858 1/20 0.35
KDM5B Q9UGL1 2/20 0.34
JAK2 O60674 1/20 0.34
TYK2 P29597 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.33
CDK8 P49336 1/20 0.33
CDK19 Q9BWU1 1/20 0.33
BMPR1A P36894 1/20 0.33
ACVRL1 P37023 1/20 0.33
ACVR1 Q04771 1/20 0.33
AXL P30530 3/20 0.33
TYRO3 Q06418 3/20 0.33
MERTK Q12866 3/20 0.33
MET P08581 1/20 0.33
RET P07949 1/20 0.33
CREBBP Q92793 3/20 0.31
BRD4 O60885 2/20 0.31
PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257766 0.81 IRAK4 (0.43) KDM5APDK2KDM5BJAK2TYK2
SCHEMBL24257502 0.76 GRM4 (0.53) KDM5A
SCHEMBL24257581 0.75 RET (0.38) KDM5APDK2JAK2TYK2RET
SCHEMBL24257535 0.74 GRM4 (0.45) KDM5BJAK2IRAK4AXL
SCHEMBL24257531 0.73 GRM5 (0.52)
SCHEMBL24257737 0.73 IRAK4 (0.47) JAK2IRAK4MET
SCHEMBL30453043 0.72 KDM4E (0.38)
SCHEMBL24257513 0.72 KDM4E (0.38)
SCHEMBL24257763 0.71 KDM4E (0.35) PDK2PIK3CD
SCHEMBL30546870 0.71 KDM4E (0.35) PDK2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 KDM5A 199/4885PDK2 762/4885SCN9A 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.